News
At Teclison, we are developing new drugs to treat cancer and other diseases with strong unmet medical need.
Out-licensing development of TEC-001 in China to Hangzhou Raygene Pharmaceutical.
December 2020
Teclison and Hangzhou Raygene Pharmaceutical signed a licensing agreement, in which Raygene obtains commercial rights in China for TEC-001. Teclison will receive upfront, milestone, and future royalty payments from this collaboration.
Announcing Collaboration with Merck.
March 2020
Teclison has entered into a clinical collaboration with Merck (known as MSD outside of the US and Canada) on March 2020 to evaluate our therapy in combination with pembrolizumab.
Gold Medal at 7th China Healthcare Innovation Competition, Shenzhen, China
August 2018
Our China subsidiary, Hangzhou Taibo Medicine Technology Ltd., presented in the 7th China Healthcare Innovation Competition at Shenzhen, China, on Aug. 2018 and won the Gold medal among 400 competitors.
The First China Medical Innovation Competition at Boao (博鳌), Hainan, China
April 2018
Dr. Haikun Shi, the Chief Medical Officer of the Hangzhou Taibo Medicine Technology LLC., the China Subsidiary of Teclison Limited, presented the liver cancer project at the First China Medical Innovation Competition at Boao (博鳌), Hainan, China and received the Gold award among over 300 projects.
Orphan Drug Granted From FDA And EMA
June 2017
Orphan drug has been granted from FDA in October 2015 and EMA in June 2017. An orphan drug designation allows exclusive right for 7 years in US and 10 years in EU along with other incentives in US.
Global Regulatory Consultation
May 2017
FDA has endorsed our dose selection and clinical developmental strategies in EOP1 meeting in May 2017 for future market application. China CFDA and EU MPA are also aligned with the comments from US FDA.
EASL Presentation
April 2017
First presentation of the phase I study showed that TPZ is well tolerated when combined with trans-arterial embolization. This combination leads to a high complete response rate with a long duration for patients with intermediate stage liver cancer. The study achieves the goal of proof-of-concept and supports the subsequent randomized trials.
Contact Us
New Jersey:
26 Park Street, Suite 100,
Montclair, NJ 07042
Taiwan:
10F., No.124, Sec. 2, Nanjing East Road,
Taipei, Taiwan (R.O.C.) 10489
Email:
info@teclison.com